Tß4 is a synthetic version of a naturally occurring peptide present in virtually all human cells. The preclinical studies of this multi-functional molecule has shown to promote endothelial
The successful inspection comes following Axxess Pharma’s most recent letter of intent (LOI) to acquire a Canada-based pharmaceutical manufacturer. Axxess Pharma’s facility is roughly 22,000sqft and manufactures pharmaceuticals,
FDA has also prompted the manufacturer to develop a risk management plan aimed at educating health care professionals and patients about the potential risks. The risk management plan,
The study results, published in The New England Journal of Medicine (NEJM Vol. 362 No. 25), also demonstrated cost savings in use of the fractional-dose intradermal injection as
Merck said that this restructuring is done to create a flexible R&D organisation that facilitates external collaboration and drives pipeline progress and a fully utilised manufacturing supply chain
WSBI is currently advancing its lead molecule, WSBI-711, which is an antibody against two TCISM targets into midstage pre-clinical testing. WSBI’s other TCISM antibody and orally-active small molecule
Aciont said that the goal of the project is to develop a safe and effective ocular iontophoresis drug delivery system for high molecular weight drugs or macromolecules to
As per the terms of the agreement, AIM is expected to provide Health Evaluations; Immunizations; Ergonomic Education, Assessments and Programs; Health Education, Promotion and Training; and Workplace Investigations.
In addition to the recently issued US patents, the company was granted: AU 2004241093, corresponding to US Patent No 7,569,554, entitled ‘Synergistic Treatment of Cancer Using Immunomers in
LANL also expects to develop a validated assay to detect human tuberculosis using a currently known biomarker to be used in combination with the waveguide-based optical biosensor platform
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.